Why the study?
Variants near growth hormone and IGF system genes associate with height, but the mechanisms underlying these genetic associations and gene regulation affecting growth remain poorly understood.
Cross-Sectional (n=838)
Yes
Standardized Mean Difference: 0.061 (95% CI 0.053–0.069)
Genetic variants regulating serum levels of IGF-related proteins in childhood colocalize with specific growth phenotypes like sitting height ratio and birth weight, but not overall height.
No immediate clinical implications for growth assessment; extends genetic evidence for IGFBP-3 in segmental proportions.
The growth hormone and insulin-like growth factor (IGF) system is integral to human growth. Genome-wide association studies (GWAS) have identified variants associated with height and located near the genes in this pathway. However, mechanisms underlying these genetic associations are not understood. To investigate the regulation of the genes in this pathway and mechanisms by which regulation could affect growth, we performed GWAS of measured serum protein levels of IGF-I, IGF binding protein-3 (IGFBP-3), pregnancy-associated plasma protein A (PAPP-A2), IGF-II and IGFBP-5 in 838 children (3-18 years) from the Cincinnati Genomic Control Cohort. We identified variants associated with protein levels near IGFBP3 and IGFBP5 genes, which contain multiple signals of association with height and other skeletal growth phenotypes. Surprisingly, variants that associate with protein levels at these two loci do not colocalize with height associations, confirmed through conditional analysis. Rather, the IGFBP3 signal (associated with total IGFBP-3 and IGF-II levels) colocalizes with an association with sitting height ratio (SHR); the IGFBP5 signal (associated with IGFBP-5 levels) colocalizes with birth weight. Indeed, height-associated single nucleotide polymorphisms near genes encoding other proteins in this pathway are not associated with serum levels, possibly excluding PAPP-A2. Mendelian randomization supports a stronger causal relationship of measured serum levels with SHR (for IGFBP-3) and birth weight (for IGFBP-5) than with height. In conclusion, we begin to characterize the genetic regulation of serum levels of IGF-related proteins in childhood. Furthermore, our data strongly suggest the existence of growth-regulating mechanisms acting through IGF-related genes in ways that are not reflected in measured serum levels of the corresponding proteins.
No takes yet. Share an insight, caveat, or question.
Bartell et al. (2020) conducted a cross-sectional in Growth biology and skeletal growth phenotypes (n=838). Genetically determined total IGFBP-3 levels vs. Lower genetically determined levels was evaluated on Sitting height ratio (SHR) (0.061 SD increase, 95% CI 0.053-0.069).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: